Ciclosporin A topical - BioNanoSim/Immune Pharmaceuticals

Drug Profile

Ciclosporin A topical - BioNanoSim/Immune Pharmaceuticals

Alternative Names: CsA - Immune Pharmaceuticals; Cyclosporine-A - Immune Pharmaceuticals; Nano-cyclosporine A - Immune Pharmaceuticals; Nano-formulated cyclosporine A - Immune Pharmaceuticals; Nanocyclo

Latest Information Update: 25 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Hebrew University of Jerusalem; Immune Pharmaceuticals Inc
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Atopic dermatitis; Psoriasis

Most Recent Events

  • 20 Feb 2018 Immune Pharmaceuticals plans a proof-of-concept trial for Psoriasis in 2H 2018
  • 16 Aug 2016 Immune Pharmaceuticals plans to file an IND application for Atopic dermatitis and Psoriasis in 2017
  • 16 May 2016 Immune Pharmaceuticals plans a phase II trial for Atopic dermatitis and Psoriasis in
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top